Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma
Innovation, not easy money, is behind the Nasdaq's return to 5,000
Research and Markets: Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts'
Research and Markets: Dyslipidemia Therapeutics Pipeline Review 2015 - 35 Companies & 49 Drug Profiles
These top investment managers put new money to work in several wide-moat names, including United Technologies.
UPDATE: CVS girds for battle over cholesterol drugs
CVS girds for battle over cholesterol drugs
Daniel Loeb's Third Point boosts stock holdings, adding new stakes in Citigroup and Delta
Research and Markets: Global Erythropoietin Drugs Market (Products, Applications and Geography) - Size, Global Trends, Company Profiles, Segmentation and Forecast, 2013 - 2020
Compugen Expands and Strengthens Business Development Team